Asset Details
Do you wish to reserve the book?
A prospective study on a weight control program and its impact on regional and total body composition in post-menopausal women
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A prospective study on a weight control program and its impact on regional and total body composition in post-menopausal women
Do you wish to request the book?
A prospective study on a weight control program and its impact on regional and total body composition in post-menopausal women
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Dissertation
A prospective study on a weight control program and its impact on regional and total body composition in post-menopausal women
1998
Overview
Forty-five obese postmenopausal Caucasian women were treated with phentermine hydrochloride (Fastin®) and a 1200 kcal diet for weight reduction. Total and regional body composition changes were measured by dual-energy X-ray absorptiometry (DXA) and by anthropometry at 3-mo intervals over 9 mo. Plasma lipids, and serum insulin and leptin were measured. After 3 mo, Fastin® therapy produced a 6.8 kg weight loss (P < 0.01), and DXA-assessed fat and lean mass losses (P < 0.01) of 11.9 and 3.0%. respectively. DXA-estimated regional composition revealed respective fat mass losses of 14.1 and 11.9%. From abdomen and thighs, suggesting primarily subcutaneous and central fat depot losses. DXA reliability was assessed by same-day duplicate measurements ( n = 10) calculated using old (version 8.1a) and new (version 8.21) analysis software. A 1.5% between-duplicate difference in lean mass was obtained with the old software; the new software yielded 1.1, 1.4 and 1.6% differences between duplicates for fat, lean and leg lean masses, respectively. CVs ranged from 1.7% for bone mineral content to 12.0% for arm fat mass for both versions. The new software produced higher values for all variables, except arm fat and lean masses than the old software. Except for a 1.9% trunk fat loss detected with the old software, magnitude of body composition changes over 3 mo in 21 weight-stable subjects was the same. The new software estimated total weight more accurately and with less variability than the old software. Fastin®-treated women lost (P < 0.01) 10% of their baseline body weight over 9 mo which correlated with a 20% reduction (P < 0.01) in serum leptin concentration. Plasma HDL-cholesterol concentration increased (P < 0.01) by 15% over 9 mo while total- and LDL-cholesterol and triglycerides decreased 14.2 (P < 0.01), 25.4 (P < 0.01) and 12.2% (P < 0.05), respectively. Serum insulin was unaffected by weight reduction. These data suggest that Fastin® therapy was effective in reducing weight, and in producing a healthier body fat distribution and plasma lipid profile, thereby lowering cardiovascular disease risk in obese postmenopausal women. The DXA instrument (Holologic QDR-4500A. Hologic Inc. Waltham, MA) gave reproducible estimates of composition change in this population regardless of the software version used.
Publisher
ProQuest Dissertations & Theses
Subject
ISBN
059910368X, 9780599103689
